We recently published a list of Smart Money Ratings For 20 Most Undervalued Stocks. In this article, we are going to take a look at where Immunovant, Inc. (NASDAQ:IMVT) stands against other most undervalued stocks with smart money ratings.
We have passed a quarter into 2025, and the U.S. economy sends mixed signals, causing investors to scramble and decode them. The U.S. GDP contracted by 0.3% in Q1, 2025, as businesses started stockpiling imports at a record pace to brace themselves for the sweeping tariffs introduced by President Trump. Not considering the pandemic era, goods imports have never been this high since 1974.
In addition to dragging the economic growth lower, the rising imports and declining GDP have left even economists unsure of what comes next. Some tend to dismiss the slump as a temporary blip induced by changes in trade policies. Others are raising the alarm about a crack in the economy, influenced by stubborn inflation and slowing consumer spending.
READ ALSO: 10 Stocks with Insanely High PE Ratios Insiders Are Selling
In the middle of this uncertain period, the Federal Reserve is presented with two options: cut rates to stimulate growth or hold firm to control inflation. As per a CNBC report, there is an upward movement in Core Personal Consumption Expenditures (PCE) prices by 3.5% year-over-year in Q1, well above the Fed’s anticipated 2%. The increase comes while the consumer spending growth has cooled to 1.8%, marking the weakest pace in the last two years.
Pointing to these cross signals, Chair Jerome Powell ruled out pre-emptive rate cuts and advocated trade negotiations to influence the current economic condition, either for better or worse. These claims have got the market on edge. Every headline about tariffs or Treasury yields is sending ripples through portfolios.
Opportunities are also on the rise amid the uncertainty. Historically, the undervalued stocks, trading below their actual worth owing to short-term fears arising from economic ambiguity, have outperformed even their counterparts when the market sentiment shifted. After the 2008 financial crisis, for instance, in 2009, the value stocks representing the market rebounded by 58%, beating the returns of their growth peers. Such a history would repeat itself in the current market environment if investors were to focus on stocks with strong fundamentals that are being overlooked.
We must separate the noise from the nuance to focus on the right stocks. Most of the headlines are fixated on tariffs and GDP dips. While these indicators should not be ignored, we must also look at the underlying strengths that would persist. Some companies are upgrading their equipment in anticipation of potential supply chain disruptions, causing the private domestic investment to increase by 21.9% in Q1. The unemployment rate has not risen from 4.2%, and the April payrolls added 177,000 jobs, indicating the labor market’s strong footing. These divergences point to an environment that invites bargaining opportunities for investors.
This brings us to our carefully curated list of smart money ratings for the 20 most undervalued stocks with strong growth potential. Going through their fundamentals, we have compiled a list of 20 companies trading at discounts far away from their long-term potential. Be it a tech firm undervalued due to tariff fears, or an industrial giant priced for recession. Our picks reflect a simple truth: markets overreact, but fundamentals endure.
Our Methodology
We have used a few criteria when putting together our list of 20 undervalued stocks with smart money ratings. Primarily, we have only considered those stocks with a value that has gained less than 12% from their 52-week lows. All the picks on our list also have a price-to-earnings ratio of less than 25. We ensured that the stock’s value remained at least 20% below its average analyst target price. Together, the P/E ratio and upside potential represent the undervaluation of the stock in the market at a price beneficial to the investors. For listing our picks, we have used the stocks’ upside potential. All the data in the article was taken from financial databases and analyst reports, with all information updated as of May 08, 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
A closeup of a scientist working with a microscope in a biotech laboratory.
Immunovant, Inc. (NASDAQ:IMVT)
Insider Transaction: 19.69%
Upside Potential: 253.11%
Forward P/E: 0.00
Immunovant, Inc. (NASDAQ:IMVT) is a clinical-stage biotechnology company headquartered in New York. The company specializes in developing targeted therapies for autoimmune diseases. Its flagship product, IMVT-1402, is an FcRn inhibitor that helps treat conditions like myasthenia gravis and thyroid eye disease. Immunovant, Inc. (NASDAQ:IMVT) signifies a differentiated safety and efficacy profile in which trial progression takes priority, but investor confidence, regulatory approval timelines, and therapeutic market expansion have some level of influence on the company’s growth. The company has yet to generate any profit as it is still in the development phase.
The company’s value is 12.19% above its 52-week low, showing upward movement. Although Immunovant, Inc. (NASDAQ:IMVT) reported a significant net loss of $111.1 million for the quarter ending December 31, 2024, the company stands strong in its cash position with a value of approximately $825 million. In addition to funding ongoing pivotal trials, this substantial capital allows the company to expand R&D efforts across ten planned indications. The company is also making significant progress with its lead asset IMVT-1402. The asset has cleared six Investigational New Drug (IND) applications. It has entered pivotal studies in Graves’ disease and difficult-to-treat rheumatoid arthritis, increasing its potential to generate significant revenue in the upcoming years.
Insider buying signals internal optimism, jumping to 19.69% in the past six months. Hedge fund involvement is strong, with 35 participants holding on to the company’s stakes. The forward P/E ratio of 0.00 indicates that the market valuation has not yet considered the company’s future growth potential. With a staggering upside potential of 253.11%, Immunovant, Inc. (NASDAQ:IMVT) stands out as the most undervalued in our list, with bullish sentiment across the board.
Overall, IMVT ranks 1st on our list of most undervalued stocks with smart money ratings. While we acknowledge the potential of IMVT, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than IMVT but trades at less than 5 times its earnings, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
